Clinical lymphoma, myeloma & leukemia

Keyphrases

Publications

volume 24, number 6, 2024

Samuel Yamshon, Caitlin Gribbin, Mohammad Alhomoud, Nora Chokr, Zhengming Chen, Michelle Demetres, Michelle Pasciolla, John Leonard, Tsiporah Shore, Peter Martin
Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis. Clinical lymphoma, myeloma & leukemia 24 (6) (2024)
Qianwen Shang, Lian Xue, Aidong Lu, Yueping Jia, YingXi Zuo, Huimin Zeng, Leping Zhang
Efficacy and Safety of Children With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After Anti-CD19 CAR T-Cell Therapy Without Bridging Transplantation. Clinical lymphoma, myeloma & leukemia 24 (6) (2024)
Noopur S Raje, Adam D Cohen, Krina K Patel, Niels W C J van de Donk, Joshua Richter, Jesus San-Miguel
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting. Clinical lymphoma, myeloma & leukemia 24 (6) (2024)
Hang Quach, Gurdeep Parmar, Maria-Victoria Mateos, Sikander Ailawadhi, Xavier Leleu
Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma. Clinical lymphoma, myeloma & leukemia 24 (6) (2024)
Fathima Shehnaz Ayoobkhan, Al-Ola Abdallah, Faiz Anwer, Nausheen Ahmed
Dampening Logistics Creating Inequitable Access: A Major Threat Despite Advancements. Clinical lymphoma, myeloma & leukemia 24 (6) (2024)
Julio C Chavez, Ariel Grajales, Jose Sandoval-Sus, Elyce Turba, Lisa Nodzon, Angimar Uriepero-Palma, Mohammad Ammad-Ud-Din, Eva Sahakian, Rami Komrokji, Lubomir Sokol, Frederick L Locke, Bijal Shah, Jeffrey Lancet, Eduardo M Sotomayor, Mohamed A Kharfan-Dabaja, Celeste Bello, Javier Pinilla-Ibarz
Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis. Clinical lymphoma, myeloma & leukemia 24 (6) (2024)
Xiaoshuai Zhang, Na Xu, Yunfan Yang, Hai Lin, Bingcheng Liu, Xin Du, Xiaoli Liu, Rong Liang, Chunyan Chen, Jian Huang, Huanling Zhu, Ling Pan, Xiaodong Wang, Guohui Li, Zhuogang Liu, Yanqing Zhang, Zhenfang Liu, Jianda Hu, Chunshui Liu, Fei Li, Wei Yang, Li Meng, Yanqiu Han, Li'e Lin, Zhenyu Zhao, Chuanqing Tu, Caifeng Zheng, Yanliang Bai, Zeping Zhou, Suning Chen, Huiying Qiu, Lijie Yang, Xiuli Sun, Hui Sun, Li Zhou, Zelin Liu, Danyu Wang, Jianxin Guo, Liping Pang, Qingshu Zeng, Xiaohui Suo, Weihua Zhang, Yuanjun Zheng, Yanli Zhang, Weiming Li, Qian Jiang
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study. Clinical lymphoma, myeloma & leukemia 24 (6) (2024)
Lucas Castelo, Wellington Fernandes da Silva, Marco Lincango, Valeria Buccheri, Agustina Perusini, Jorge Arbelbide, Marcelo Iastrebner, Jacqueline Gonzalez, Patricio Pereyra, Thales Dalessandro M Pereira, Luan Lima Marchi, Vanderson Rocha, Carolina B Belli, Elvira Deolinda Rodrigues Pereira Velloso
Alternative Dosing Schedules of Azacitidine: A Real-World Study Across South American Centers. Clinical lymphoma, myeloma & leukemia 24 (6) (2024)
Hira Mian, Hsien Seow, Gregory R Pond, Anastasia Gayowsky, Ronan Foley, Amaris Balistky, Mohammed Ebraheem, Christopher Cipkar, Hyra Sapru, Ghulam Rehman Mohyuddin, Samer Al Hadidi, Alissa Visram
Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. Clinical lymphoma, myeloma & leukemia 24 (6) (2024)
Filip Ionescu, Jerel C David, Apoorva Ravichandran, David A Sallman, Kendra Sweet, Rami S Komrokji, Onyee Chan, Andrew Kuykendall, Eric Padron, Rawan Faramand, Nelli Bejanyan, Farhad Khimani, Hany Elmariah, Joseph Pidala, Asmita Mishra, Lia Perez, Taiga Nishihori, Jeffrey E Lancet
Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant. Clinical lymphoma, myeloma & leukemia 24 (6) (2024)

volume 24, number 7, 2024

Cameron Clark, Jack Goddard, Rachel Tattersall, Nick Morley
Average Temperature as a Marker of Lymphoma-Associated HLH. Clinical lymphoma, myeloma & leukemia 24 (7) (2024)
Efstathios Kastritis, Ioannis Ntanasis-Stathopoulos, Foteini Theodorakakou, Magdalini Migkou, Maria Roussou, Panagiotis Malandrakis, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Vassiliki Spiliopoulou, Maria Gavriatopoulou, Sachin Patel, Istvan Majer, Christos Boukis, Andriani Fetani, Meletios A Dimopoulos, Evangelos Terpos
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece. Clinical lymphoma, myeloma & leukemia 24 (7) (2024)
Lara Gallucci Figorelle, Peterson Tiago Galvão, Felipe Matheus Ribeiro de Lima, Patricia Marimon, Nathalia Pentagna, Cristiane Milito, Rony Schaffel, Katia Carneiro
Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions. Clinical lymphoma, myeloma & leukemia 24 (7) (2024)
Paola Negrete-Rodríguez, Moisés Manuel Gallardo-Pérez, Olivia Lira-Lara, Miranda Melgar-de-la-Paz, Luis Enrique Hamilton-Avilés, Guillermo Ocaña-Ramm, Max Robles-Nasta, Daniela Sánchez-Bonilla, Juan Carlos Olivares-Gazca, María-Victoria Mateos, Guillermo J Ruiz-Delgado, Guillermo J Ruiz-Argüelles
Prevalence and Consequences of a Delayed Diagnosis in Multiple Myeloma: A Single Institution Experience. Clinical lymphoma, myeloma & leukemia 24 (7) (2024)
Nicholas J Short, Elias Jabbour, Hagop Kantarjian
SOHO State of the Art Updates and Next Questions, Measurable Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clinical lymphoma, myeloma & leukemia 24 (7) (2024)
Rahul Banerjee, Andrew J Cowan, Marivel Ortega, Constance Missimer, Paul A Carpenter, Masumi Ueda Oshima, Rachel B Salit, Phuong T Vo, Catherine J Lee, Rohtesh S Mehta, Nicole M Kuderer, Veena Shankaran, Stephanie J Lee, Christopher T Su
Financial Toxicity, Time Toxicity, and Quality of Life in Multiple Myeloma. Clinical lymphoma, myeloma & leukemia 24 (7) (2024)
Rahul Banerjee, Andrew J Cowan, Marivel Ortega, Constance Missimer, Paul A Carpenter, Masumi Ueda Oshima, Rachel B Salit, Phuong T Vo, Catherine J Lee, Rohtesh S Mehta, Nicole M Kuderer, Veena Shankaran, Stephanie J Lee, Christopher T Su
Financial Toxicity, Time Toxicity, and Quality of Life in Multiple Myeloma. Clinical lymphoma, myeloma & leukemia 24 (7) (2024)
Rahul Banerjee, Andrew J Cowan, Marivel Ortega, Constance Missimer, Paul A Carpenter, Masumi Ueda Oshima, Rachel B Salit, Phuong T Vo, Catherine J Lee, Rohtesh S Mehta, Nicole M Kuderer, Veena Shankaran, Stephanie J Lee, Christopher T Su
Financial Toxicity, Time Toxicity, and Quality of Life in Multiple Myeloma. Clinical lymphoma, myeloma & leukemia 24 (7) (2024)
Chandramouli Nagarajan, Martin Wong Eu Jo, Thomas G Martin
BCMA Directed Bispecific Antibody Induced Tumor Flare in Multiple Myeloma. Clinical lymphoma, myeloma & leukemia 24 (7) (2024)
Pankit Vachhani, Sanam Loghavi, Prithviraj Bose
SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis. Clinical lymphoma, myeloma & leukemia 24 (7) (2024)
Fadi G Haddad, Cedric Nasnas, Koji Sasaki, Shilpa Paul, Ghayas C Issa, Caitlin Rausch, Elias Jabbour, Hagop Kantarjian
Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib. Clinical lymphoma, myeloma & leukemia 24 (7) (2024)
Luis E Aguirre, Akriti Jain, Somedeb Ball, Najla Al Ali, Virginia O Volpe, Sara Tinsley-Vance, David Sallman, Kendra Sweet, Jeffrey Lancet, Eric Padron, Seongseok Yun, Andrew Kuykendall, Rami Komrokji
Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes. Clinical lymphoma, myeloma & leukemia 24 (7) (2024)

volume 24, number 8, 2024

Matthew Mei, Ni-Chun Tsai, Joycelynne Palmer, Saro Armenian, Robert Chen, Steven Rosen, Stephen Forman, Leslie Popplewell, Larry Kwak, Peter Martin, Kami Maddocks, David Bond, Alex F Herrera
Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma. Clinical lymphoma, myeloma & leukemia 24 (8) (2024)
Abdulraheem Yacoub, Nicole Twardowski, Alec Britt, Nour Shraim
SOHO State of the Art Updates and Next Questions | Early Intervention in Myelofibrosis: Where Are We and Does It Matter? Clinical lymphoma, myeloma & leukemia 24 (8) (2024)
Andrew T Kuykendall, Jennifer T Fine, Marina Kremyanskaya
Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians. Clinical lymphoma, myeloma & leukemia 24 (8) (2024)
Joshua Richter, Matthew S Davids, Colin Anderson-Smits, Marta Kamieniak, Kaili Ren, Michael Hull, Jasjit K Multani, Drishti Shah, Csaba Siffel
Burden of Infection in Patients With and Without Secondary Immunodeficiency Disease Following Diagnosis of a Mature B Cell Malignancy. Clinical lymphoma, myeloma & leukemia 24 (8) (2024)
Naohiro Matsunaga, Tomotaka Suzuki, Nozomi Nishitarumizu, Yoko Nakanishi, Aki Kondo, Yukiyasu Kato, Toru Ebina, Yoshiaki Marumo, Tomoyuki Nakamura, Takahiro Nakashima, Shiori Kinoshita, Tomoko Narita, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida
Clinical Significance of Cytomegalovirus Reactivation in Patients With Plasma Cell Dyscrasia Who Were Treated With Anti-CD38 Monoclonal Antibody: A Retrospective Analysis in a Single Institution. Clinical lymphoma, myeloma & leukemia 24 (8) (2024)
Kathryn Lurain, Talal El Zarif, Ramya Ramaswami, Amin H Nassar, Elio Adib, Noha Abdel-Wahab, Nikita Chintapally, Claire E Drolen, Tatyana Feldman, Tarek Haykal, Caroline A Nebhan, Swetha Kambhampati, Mingjia Li, Arjun Mittra, Michael Lorentsen, Chul Kim, Alexandra Drakaki, Michael Morse, Douglas B Johnson, Ankit Mangla, Christopher Dittus, Praful Ravi, Robert A Baiocchi, Elizabeth Y Chiao, Paul G Rubinstein, Sarvari V Yellapragada, Ann S LaCasce, Guru P Sonpavde, Abdul Rafeh Naqash, Alex F Herrera
Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States. Clinical lymphoma, myeloma & leukemia 24 (8) (2024)
Andrew Ip, Alexandra Della Pia, Andre H Goy
SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024. Clinical lymphoma, myeloma & leukemia 24 (8) (2024)
P Joy Ho, Andrew Spencer, Peter Mollee, Christian E Bryant, Anoop K Enjeti, Noemi Horvath, Belinda E Butcher, Judith Trotman, Simon Gibbs, Douglas E Joshua
Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment-An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse. Clinical lymphoma, myeloma & leukemia 24 (8) (2024)
Kathryn Lurain, Talal El Zarif, Ramya Ramaswami, Amin H Nassar, Elio Adib, Noha Abdel-Wahab, Nikita Chintapally, Claire E Drolen, Tatyana Feldman, Tarek Haykal, Caroline A Nebhan, Swetha Kambhampati, Mingjia Li, Arjun Mittra, Michael Lorentsen, Chul Kim, Alexandra Drakaki, Michael Morse, Douglas B Johnson, Ankit Mangla, Christopher Dittus, Praful Ravi, Robert A Baiocchi, Elizabeth Y Chiao, Paul G Rubinstein, Sarvari V Yellapragada, Ann S LaCasce, Guru P Sonpavde, Abdul Rafeh Naqash, Alex F Herrera
Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States. Clinical lymphoma, myeloma & leukemia 24 (8) (2024)

volume 24, number 9, 2024

Daryl Tan, Jason Yongsheng Chan, Kitsada Wudhikarn, Raymond Siu Ming Wong, Limei Poon, Lalita Norasetthada, Tai-Chung Huang, Eric Tse
Unmet Needs in the First-Line Treatment of Diffuse Large B-cell Lymphoma: Expert Recommendations From the Asia-Pacific Region With a Focus on the Challenging Subtypes. Clinical lymphoma, myeloma & leukemia 24 (9) (2024)
Ayushi Chauhan, Catherine Lai, Frank Kuhr, Heidi Simmons, Bruce D Cheson
Long-Term Follow-Up of Patients With Follicular Lymphoma Using Next Generation Sequencing to Detect Minimal Residual Disease. Clinical lymphoma, myeloma & leukemia 24 (9) (2024)
Koji Sasaki, Hagop Kantarjian, Guillermo Montalban-Bravo, Danielle Hammond, Elias Jabbour, Rashmi Kanagal-Shamanna, Kelly Chien, Guillermo Garcia-Manero
Eosinophilia During Lenalidomide Therapy in Myelodysplastic Syndrome. Clinical lymphoma, myeloma & leukemia 24 (9) (2024)
Wei-Ying Jen, Elias Jabbour, Hagop M Kantarjian, Nicholas J Short
SOHO State of the Art Updates and Next Questions | Novel Agents and the Diminishing Role of Allogeneic Stem Cell Transplant in B-Acute Lymphoblastic Leukemia. Clinical lymphoma, myeloma & leukemia 24 (9) (2024)
Janine M Joseph, Michaela Hillengass, Rikki Cannioto, Joseph D Tario, Paul K Wallace, Kristopher Attwood, Adrienne Groman, Hillary Jacobson, Bryan Wittmeyer, Hemn Mohammadpour, Scott I Abrams, Kirsten B Moysich, Jens Hillengass
T Cell Exhaustion Markers in Multiple Myeloma Patients are Lower After Physical Activity Intervention. Clinical lymphoma, myeloma & leukemia 24 (9) (2024)
Janine Kirchberg, Luise Fischer, Patrick Born, Franziska Brunner, Charlotte Morgner, Daniel Fürst, Simone Heyn, Enrica Bach, Mandy Brueckner, Madlen Jentzsch, Song-Yau Wang, Sebastian Böttcher, Georg-Nikolaus Franke, Hubert Schrezenmeier, Uwe Platzbecker, Maximilian Merz, Vladan Vučinić
Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia 24 (9) (2024)
Michael J Hochman, Amy E DeZern
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes. Clinical lymphoma, myeloma & leukemia 24 (9) (2024)
Janine Kirchberg, Luise Fischer, Patrick Born, Franziska Brunner, Charlotte Morgner, Daniel Fürst, Simone Heyn, Enrica Bach, Mandy Brueckner, Madlen Jentzsch, Song-Yau Wang, Sebastian Böttcher, Georg-Nikolaus Franke, Hubert Schrezenmeier, Uwe Platzbecker, Maximilian Merz, Vladan Vučinić
Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia 24 (9) (2024)
Christine Bennink, Mirian Brink, Saskia F A Duijts, Hans Scheurer, Pieter Sonneveld, Hedwig M Blommestein
Changes in income and employment after diagnosis among patients with multiple myeloma in The Netherlands. Clinical lymphoma, myeloma & leukemia 24 (9) (2024)
Tommaso Lupia, Lorenzo Cani, Sara Bringhen, Francesco Giuseppe De Rosa, Benedetto Bruno, Malgorzata Mikulska, Silvia Corcione, Roberto Mina
Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for Clinicians. Clinical lymphoma, myeloma & leukemia 24 (9) (2024)
Matthew R LeBlanc, Xi Zhou, Christopher D Baggett, Sascha A Tuchman, Christopher E Jensen, Eben I Lichtman, Samuel M Rubinstein
Second Line Therapy in Multiple Myeloma: A SEER Medicare Analysis. Clinical lymphoma, myeloma & leukemia 24 (9) (2024)
Maria Magdalena Joks, Krystian Czernikiewicz, Łukasz Mazurkiewicz, Monika Joks, Andrzej Balcerzak, Renata Kroll-Balcerzak, Joanna Rupa-Matysek
Breast Implant-Associated Anaplastic Large Cell Lymphoma: Where Hematology and Plastic Surgery Meet. Clinical lymphoma, myeloma & leukemia 24 (9) (2024)
Nilanjan Ghosh, Jeff P Sharman, Meghan Gutierrez, Wasiulla Khan, Zaina P Qureshi, Anat Raz, Vincent Girardi, Gabriel S Krigsfeld, Jacqueline C Barrientos
Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry. Clinical lymphoma, myeloma & leukemia 24 (9) (2024)
Guillermo Garcia-Manero, Rayna K Matsuno, Ali McBride, Hina Mohammed, Danny Idryo, Ronda Broome, Autumn Herriman, Tiffany Johnson, Kristiana Wilkinson, Andrew Schrag, Colden Johanson, Monika Izano, Adeola Makinde, Sudipto Mukherjee
Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents. Clinical lymphoma, myeloma & leukemia 24 (9) (2024)
Danielle Brazel, David Hermel, Pranav Gandhi, Alan Saven
Detangling the Threads of Hairy Cell Leukemia, Beyond the Morphology and Into the Molecular. Clinical lymphoma, myeloma & leukemia 24 (9) (2024)
Shivani Handa, Ganesh Sivakumar, Andrew Srisuwananukorn, Amylou Dueck, Douglas Tremblay, John O Mascarenhas, Yelena Ginzburg, Marina Kremyanskaya, Ronald Hoffman
Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy. Clinical lymphoma, myeloma & leukemia 24 (9) (2024)
Nilanjan Ghosh, Jeff P Sharman, Meghan Gutierrez, Wasiulla Khan, Zaina P Qureshi, Anat Raz, Vincent Girardi, Gabriel S Krigsfeld, Jacqueline C Barrientos
Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry. Clinical lymphoma, myeloma & leukemia 24 (9) (2024)
Shivani Handa, Ganesh Sivakumar, Andrew Srisuwananukorn, Amylou Dueck, Douglas Tremblay, John O Mascarenhas, Yelena Ginzburg, Marina Kremyanskaya, Ronald Hoffman
Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy. Clinical lymphoma, myeloma & leukemia 24 (9) (2024)
Zachary Brown, Campbell Scott, Li Fang Zhang, Ramses Sadek, Andrea Clarke, Anand Jillella, Amany R Keruakous, Amber B Clemmons
Assessing Outcomes in Patients With Multiple Myeloma Postautologous Stem Cell Transplantation: Contrasting the Effects of Melphalan Dosages at 200 mg/m 2 versus 140 mg/m 2 . Clinical lymphoma, myeloma & leukemia 24 (9) (2024)